Consultancy Eignapharma, member of CataloniaBio & HealthTech, has reached a collaboration agreement with Biogem, an Italian consortium specialised in lab scale development and production of biosimilars, monoclonal antibodies, new biological entities and related preclinical studies.

Under this agreement Eignapharma will use its commercial efforts to put at the industry disposal Biogem’s research and development capabilities consisting on documented small-scale processes and fully protocolised technology transfers procedures to allow a safe scaleup to industrial production.

Biogem is conformed by the Italian National Research Council (CNR),the Area Science Park of Trieste, the University of Naples "Federico II", the University of Milano ...


Photo gallery

The biomedicine, innovative medical technology and health ecosystem in Catalonia is maturing and there are more and more companies that experience the full business cycle through to success. Licensing deals, selling the company or commercialising the product in different markets are the main paths to this promised land. 

Palobiofarma, STAT-Dx and NEOS Surgery are good examples. CataloniaBio & HealthTech invited their founders and general managers to the Lessons Learned debate forum, on 4 July at the Barcelona Science Park (PCB) to share their experiences and the lessons they've learned with new start-ups and spin-offs. The session ...


The Spanish Bioindustry Association (Asebio) presented the Asebio Report 2017 with the latest data on the Spanish biotechnology sector on 9 July in Madrid.

One of the most noteworthy figures is the investment raised, €150 million, up 17% from 2016. Also, the sector's impact on the economy as a whole, generating 7.8% of the GDP and 108,000 jobs.

The number of companies in the sector has dropped by more than 200, from 2,981 to 2,767 in 2016. By area of activity, 66.8% focus on human health and 23.5% on food. R&D investment totalled €617 ...


Biopharmaceutical firm Spherium Biomed has begun phase-I clinical trials on their product Cilakin to prevent acute kidney failure based on more than 10 yearsof research conducted by Dr Alberto Tejedor and Dr Alberto Lázaro at Hospital Gregorio Marañón in Madrid. Spherium acquired the licence in 2015 in order to develop an injectable drug suitable for patients (more than 3 million cases each year in Europe, the United States and Japan).

"Cilakin could become the first standardised preventative treatment for this condition," explains Dr Montserrat Cano, head ofthe project at Spherium. The mortality rate can be up to 70% in ...


Dr Jordi Mestres, founder and CEO of CataloniaBio & HealthTech member Chemotargets and coordinator of the Systems Pharmacology Group at the Hospital del Mar Research Institute (IMIM), has been admitted as a fellow of the Royal Society of Chemistry

This recognition, one of the most important granted to a chemist, is an important milestone in a researcher's career because it is indicative of scientific quality.

The Royal Society of Chemistry has more than 54,000 members around the world and heritage spanning over 175 years. Its mission is to advance the chemical sciences by investing in educating future ...